{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T21:40:11Z","timestamp":1729114811696,"version":"3.27.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00393-024-01537-4","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T12:01:57Z","timestamp":1721217717000},"page":"620-628","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Head-to-Head-Studien bei Kollagenosen und Vaskulitiden","Head-to-head studies on connective tissue diseases and vasculitides"],"prefix":"10.1007","volume":"83","author":[{"given":"Bernhard","family":"Hellmich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Mucke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"1537_CR1","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/asn.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel\u00a0GB, Contreras\u00a0G, Dooley\u00a0MA et\u00a0al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J\u00a0Am Soc Nephrol 20:1103\u20131112. https:\/\/doi.org\/10.1681\/asn.2008101028","journal-title":"J Am Soc Nephrol"},{"key":"1537_CR2","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/annrheumdis-2011-200384","volume":"71","author":"S Arends","year":"2012","unstructured":"Arends\u00a0S, Grootscholten\u00a0C, Derksen\u00a0RH et\u00a0al (2012) Long-term follow-up of a\u00a0randomised controlled trial of azathioprine\/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis 71:966\u2013973. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200384","journal-title":"Ann Rheum Dis"},{"key":"1537_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00393-013-1213-y","volume":"72","author":"M Aringer","year":"2013","unstructured":"Aringer\u00a0M, Fischer-Betz\u00a0R, Hiepe\u00a0F (2013) Statement on the use of mycophenolate mofetil for systemic lupus erythematosus. ZRheumatol 72:575\u2013580","journal-title":"Z.Rheumatol."},{"key":"1537_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/s0002-9394(03)00326-x","volume":"136","author":"AM Avunduk","year":"2003","unstructured":"Avunduk\u00a0AM, Avunduk\u00a0MC, Varnell\u00a0ED et\u00a0al (2003) The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a\u00a0clinical and immunocytochemical study. Am J Ophthalmol 136:593\u2013602. https:\/\/doi.org\/10.1016\/s0002-9394(03)00326-x","journal-title":"Am J Ophthalmol"},{"key":"1537_CR5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1177\/0961203312442259","volume":"21","author":"W Chen","year":"2012","unstructured":"Chen\u00a0W, Liu\u00a0Q, Chen\u00a0W et\u00a0al (2012) Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a\u00a0multicenter randomized clinical trial. Lupus 21:944\u2013952. https:\/\/doi.org\/10.1177\/0961203312442259","journal-title":"Lupus"},{"key":"1537_CR6","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung\u00a0SA, Langford\u00a0CA, Maz\u00a0M et\u00a0al (2021) 2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 73:1366\u20131383. https:\/\/doi.org\/10.1002\/art.41773","journal-title":"Arthritis Rheumatol"},{"key":"1537_CR7","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7","volume":"42","author":"PJ Clements","year":"1999","unstructured":"Clements\u00a0PJ, Furst\u00a0DE, Wong\u00a0WK et\u00a0al (1999) High-dose versus low-dose D\u2011penicillamine in early diffuse systemic sclerosis: analysis of a\u00a0two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42:1194\u20131203. https:\/\/doi.org\/10.1002\/1529-0131(199906)42:6%3C1194::Aid-anr16%3E3.0.Co;2-7","journal-title":"Arthritis Rheum"},{"key":"1537_CR8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.22679","volume":"57","author":"P Cohen","year":"2007","unstructured":"Cohen\u00a0P, Pagnoux\u00a0C, Mahr\u00a0A et\u00a0al (2007) Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 57:686\u2013693. https:\/\/doi.org\/10.1002\/art.22679","journal-title":"Arthritis Rheum"},{"key":"1537_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMoa031855","volume":"350","author":"G Contreras","year":"2004","unstructured":"Contreras\u00a0G, Pardo\u00a0V, Leclercq\u00a0B et\u00a0al (2004) Sequential therapies for proliferative lupus nephritis. NEnglJMed 350:971\u2013980","journal-title":"N.Engl.J.Med."},{"key":"1537_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/rheumatology\/ket313","volume":"53","author":"MJ Cuadrado","year":"2014","unstructured":"Cuadrado\u00a0MJ, Bertolaccini\u00a0ML, Seed\u00a0PT et\u00a0al (2014) Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford) 53:275\u2013284. https:\/\/doi.org\/10.1093\/rheumatology\/ket313","journal-title":"Rheumatology (Oxford)"},{"key":"1537_CR11","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K De Groot","year":"2005","unstructured":"De Groot\u00a0K, Rasmussen\u00a0N, Bacon\u00a0PA et\u00a0al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:2461\u20132469. https:\/\/doi.org\/10.1002\/art.21142","journal-title":"Arthritis Rheum"},{"key":"1537_CR12","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","volume":"365","author":"MA Dooley","year":"2011","unstructured":"Dooley\u00a0MA, Jayne\u00a0D, Ginzler\u00a0EM et\u00a0al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. Nenglj Med 365:1886\u20131895","journal-title":"Nenglj Med"},{"key":"1537_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","volume":"98","author":"AS Fauci","year":"1983","unstructured":"Fauci\u00a0AS, Haynes\u00a0BF, Katz\u00a0P, Wolff\u00a0SM (1983) Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85\u00a0patients for 21\u00a0years. Ann Intern Med 98:76\u201385. https:\/\/doi.org\/10.7326\/0003-4819-98-1-76","journal-title":"Ann Intern Med"},{"key":"1537_CR14","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1002\/art.34547","volume":"64","author":"M Faurschou","year":"2012","unstructured":"Faurschou\u00a0M, Westman\u00a0K, Rasmussen\u00a0N et\u00a0al (2012) Brief Report: long-term outcome of a\u00a0randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3472\u20133477. https:\/\/doi.org\/10.1002\/art.34547","journal-title":"Arthritis Rheum"},{"key":"1537_CR15","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/ard-2022-222486","volume":"81","author":"Q Fu","year":"2022","unstructured":"Fu\u00a0Q, Wu\u00a0C, Dai\u00a0M et\u00a0al (2022) Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a\u00a0prospective, multicentre, randomised trial and long-term follow-up. Ann Rheum Dis 81:1549\u20131555. https:\/\/doi.org\/10.1136\/ard-2022-222486","journal-title":"Ann Rheum Dis"},{"key":"1537_CR16","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1001\/jama.2021.6615","volume":"325","author":"S Furuta","year":"2021","unstructured":"Furuta\u00a0S, Nakagomi\u00a0D, Kobayashi\u00a0Y et\u00a0al (2021) Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a\u00a0randomized clinical trial. JAMA 325:2178\u20132187. https:\/\/doi.org\/10.1001\/jama.2021.6615","journal-title":"JAMA"},{"key":"1537_CR17","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler\u00a0EM, Dooley\u00a0MA, Aranow\u00a0C et\u00a0al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. NEnglJMed 353:2219\u20132228","journal-title":"N.Engl.J.Med."},{"key":"1537_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/art.25052","volume":"62","author":"EM Ginzler","year":"2010","unstructured":"Ginzler\u00a0EM, Wofsy\u00a0D, Isenberg\u00a0D et\u00a0al (2010) Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a\u00a0multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 62:211\u2013221","journal-title":"Arthritis Rheum"},{"key":"1537_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/art.10922","volume":"49","author":"L Guillevin","year":"2003","unstructured":"Guillevin\u00a0L, Cohen\u00a0P, Mahr\u00a0A et\u00a0al (2003) Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a\u00a0prospective trial comparing glucocorticoids and six or twelve cylophospahmide pulses in sixty-five patients. Arthritis Rheum 49:93\u2013100","journal-title":"Arthritis Rheum"},{"key":"1537_CR20","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin\u00a0L, Pagnoux\u00a0C, Karras\u00a0A et\u00a0al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N\u00a0Engl J Med 371:1771\u20131780. https:\/\/doi.org\/10.1056\/NEJMoa1404231","journal-title":"N Engl J Med"},{"key":"1537_CR21","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/ard.2004.023937","volume":"63","author":"B Hellmich","year":"2004","unstructured":"Hellmich\u00a0B, Kausch\u00a0I, Doehn\u00a0C et\u00a0al (2004) Urinary bladder cancer in Wegener\u2019s granulomatosis: is it more than cyclophosphamide? Ann Rheum Dis 63:1183\u20131185","journal-title":"Ann Rheum Dis"},{"key":"1537_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich\u00a0B, Sanchez-Alamo\u00a0B, Schirmer\u00a0JH et\u00a0al (2024) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 83:30\u201347. https:\/\/doi.org\/10.1136\/ard-2022-223764","journal-title":"Ann Rheum Dis"},{"key":"1537_CR23","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra\u00a0TF, Walsh\u00a0M, Mahr\u00a0A et\u00a0al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a\u00a0randomized controlled trial. JAMA 304:2381\u20132388. https:\/\/doi.org\/10.1001\/jama.2010.1658","journal-title":"JAMA"},{"key":"1537_CR24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman\u00a0GS, Kerr\u00a0GS, Leavitt\u00a0RY et\u00a0al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488\u2013498. https:\/\/doi.org\/10.7326\/0003-4819-116-6-488","journal-title":"Ann Intern Med"},{"key":"1537_CR25","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1136\/ard.2010.131995","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau\u00a0FA, D\u2019cruz\u00a0D, Sangle\u00a0S et\u00a0al (2010) Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. AnnRheumDis 69:2083\u20132089","journal-title":"Ann.Rheum.Dis."},{"key":"1537_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/ard.2008.102533","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau\u00a0FA, Vasconcelos\u00a0C, D\u2019cruz\u00a0D et\u00a0al (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. AnnRheumDis 69:61\u201364","journal-title":"Ann.Rheum.Dis."},{"key":"1537_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne\u00a0D, Rasmussen\u00a0N, Andrassy\u00a0K et\u00a0al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N\u00a0Engl J Med 349:36\u201344. https:\/\/doi.org\/10.1056\/NEJMoa020286","journal-title":"N Engl J Med"},{"key":"1537_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones\u00a0RB, Tervaert\u00a0JW, Hauser\u00a0T et\u00a0al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa0909169","journal-title":"N Engl J Med"},{"key":"1537_CR29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","volume":"78","author":"RB Jones","year":"2019","unstructured":"Jones\u00a0RB, Hiemstra\u00a0TF, Ballarin\u00a0J et\u00a0al (2019) Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a\u00a0randomised, non-inferiority trial. Ann Rheum Dis 78:399\u2013405. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214245","journal-title":"Ann Rheum Dis"},{"key":"1537_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher\u00a0TM, Tudor\u00a0VA, Saunders\u00a0P et\u00a0al (2023) Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a\u00a0double-blind, double-dummy, randomised, controlled, phase\u00a02b\u00a0trial. Lancet Respir Med 11:45\u201354. https:\/\/doi.org\/10.1016\/s2213-2600(22)00359-9","journal-title":"Lancet Respir Med"},{"key":"1537_CR31","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1177\/1120672121992680","volume":"32","author":"P Moawad","year":"2022","unstructured":"Moawad\u00a0P, Shamma\u00a0R, Hassanein\u00a0D et\u00a0al (2022) Evaluation of the effect of topical tacrolimus 0.03\u202f% versus cyclosporine 0.05\u202f% in the treatment of dry eye secondary to Sjogren syndrome. Eur J Ophthalmol 32:673\u2013679. https:\/\/doi.org\/10.1177\/1120672121992680","journal-title":"Eur J Ophthalmol"},{"key":"1537_CR32","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","volume":"79","author":"CC Mok","year":"2020","unstructured":"Mok\u00a0CC, Ho\u00a0LY, Ying\u00a0SKY et\u00a0al (2020) Long-term outcome of a\u00a0randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis 79:1070\u20131076. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217178","journal-title":"Ann Rheum Dis"},{"key":"1537_CR33","doi-asserted-by":"publisher","first-page":"e001003","DOI":"10.1136\/rmdopen-2019-001003","volume":"5","author":"S Monti","year":"2019","unstructured":"Monti\u00a0S, \u00c1gueda\u00a0AF, Luqmani\u00a0RA et\u00a0al (2019) Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD open 5:e001003. https:\/\/doi.org\/10.1136\/rmdopen-2019-001003","journal-title":"RMD open"},{"key":"1537_CR34","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","volume":"76","author":"J Ordi-Ros","year":"2017","unstructured":"Ordi-Ros\u00a0J, Saez-Comet\u00a0L, Perez-Conesa\u00a0M et\u00a0al (2017) Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a\u00a0randomised clinical trial. Ann Rheum Dis 76:1575\u20131582","journal-title":"Ann Rheum Dis"},{"key":"1537_CR35","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","volume":"359","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux\u00a0C, Mahr\u00a0A, Hamidou\u00a0MA et\u00a0al (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N\u00a0Engl J Med 359:2790\u20132803. https:\/\/doi.org\/10.1056\/NEJMoa0802311","journal-title":"N Engl J Med"},{"key":"1537_CR36","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/art.39011","volume":"67","author":"C Pagnoux","year":"2015","unstructured":"Pagnoux\u00a0C, Quemeneur\u00a0T, Ninet\u00a0J et\u00a0al (2015) Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a\u00a0multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol (hoboken Nj) 67:1117\u20131127. https:\/\/doi.org\/10.1002\/art.39011","journal-title":"Arthritis Rheumatol (hoboken Nj)"},{"key":"1537_CR37","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1007\/s00296-013-2769-1","volume":"33","author":"W Qiu","year":"2013","unstructured":"Qiu\u00a0W, Liu\u00a0Z, Ao\u00a0M et\u00a0al (2013) Punctal plugs versus artificial tears for treating primary Sj\u00f6gren\u2019s syndrome with keratoconjunctivitis SICCA: a\u00a0comparative observation of their effects on visual function. Rheumatol Int 33:2543\u20132548. https:\/\/doi.org\/10.1007\/s00296-013-2769-1","journal-title":"Rheumatol Int"},{"key":"1537_CR38","doi-asserted-by":"publisher","first-page":"e396","DOI":"10.1111\/aos.14953","volume":"100","author":"M Rodr\u00edguez Calvo-De-Mora","year":"2022","unstructured":"Rodr\u00edguez Calvo-De-Mora\u00a0M, Dom\u00ednguez-Ruiz\u00a0C, Barrero-Sojo\u00a0F et\u00a0al (2022) Autologous versus allogeneic versus umbilical cord sera for the treatment of severe dry eye disease: a\u00a0double-blind randomized clinical trial. Acta Ophthalmol 100:e396\u2013e408. https:\/\/doi.org\/10.1111\/aos.14953","journal-title":"Acta Ophthalmol"},{"key":"1537_CR39","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/s0140-6736(15)01021-1","volume":"387","author":"N Ruperto","year":"2016","unstructured":"Ruperto\u00a0N, Pistorio\u00a0A, Oliveira\u00a0S et\u00a0al (2016) Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a\u00a0randomised trial. Lancet 387:671\u2013678. https:\/\/doi.org\/10.1016\/s0140-6736(15)01021-1","journal-title":"Lancet"},{"key":"1537_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00393-017-0393-2","volume":"76","author":"JH Schirmer","year":"2017","unstructured":"Schirmer\u00a0JH, Moosig\u00a0F (2017) S1 guidelines on diagnostics and treatment of ANCA-associated vasculitis. Z\u00a0Rheumatol 76:75\u201376. https:\/\/doi.org\/10.1007\/s00393-017-0393-2","journal-title":"Z Rheumatol"},{"key":"1537_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003082","author":"JH Schirmer","year":"2023","unstructured":"Schirmer\u00a0JH, Sanchez-Alamo\u00a0B, Hellmich\u00a0B et\u00a0al (2023) Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1\u2011treatment of granulomatosis with polyangiitis and microscopic polyangiitis. RMD open. https:\/\/doi.org\/10.1136\/rmdopen-2023-003082","journal-title":"RMD open"},{"key":"1537_CR42","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","volume":"57","author":"G Sircar","year":"2018","unstructured":"Sircar\u00a0G, Goswami\u00a0RP, Sircar\u00a0D et\u00a0al (2018) Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatol (oxford) 57:2106\u20132113. https:\/\/doi.org\/10.1093\/rheumatology\/key213","journal-title":"Rheumatol (oxford)"},{"key":"1537_CR43","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/ard-2022-223559","volume":"82","author":"RM Smith","year":"2023","unstructured":"Smith\u00a0RM, Jones\u00a0RB, Specks\u00a0U et\u00a0al (2023) Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Ann Rheum Dis 82:937\u2013944. https:\/\/doi.org\/10.1136\/ard-2022-223559","journal-title":"Ann Rheum Dis"},{"key":"1537_CR44","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/art.1780170602","volume":"17","author":"AD Steinberg","year":"1974","unstructured":"Steinberg\u00a0AD, Decker\u00a0JL (1974) A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum 17:923\u2013937. https:\/\/doi.org\/10.1002\/art.1780170602","journal-title":"Arthritis Rheum"},{"key":"1537_CR45","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/art.1780340803","volume":"34","author":"AD Steinberg","year":"1991","unstructured":"Steinberg\u00a0AD, Steinberg\u00a0SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34:945\u2013950","journal-title":"Arthritis Rheum"},{"key":"1537_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone\u00a0JH, Merkel\u00a0PA, Spiera\u00a0R et\u00a0al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N\u00a0Engl J Med 363:221\u2013232. https:\/\/doi.org\/10.1056\/NEJMoa0909905","journal-title":"N Engl J Med"},{"key":"1537_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan\u00a0KM, Goldmuntz\u00a0EA, Keyes-Elstein\u00a0L et\u00a0al (2018) Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. NEnglJMed 378:35\u201347","journal-title":"N.Engl.J.Med."},{"key":"1537_CR48","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin\u00a0DP, Roth\u00a0MD, Clements\u00a0PJ et\u00a0al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a\u00a0randomised controlled, double-blind, parallel group trial. Lancet Respir med 4:708\u2013719","journal-title":"Lancet Respir med"},{"key":"1537_CR49","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","volume":"20","author":"J Van De Vlekkert","year":"2010","unstructured":"Van De Vlekkert\u00a0J, Hoogendijk\u00a0JE, Haan\u00a0RJ et\u00a0al (2010) Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a\u00a0randomised clinical trial. Neuromuscul Disord 20:382\u2013389. https:\/\/doi.org\/10.1016\/j.nmd.2010.03.011","journal-title":"Neuromuscul Disord"},{"key":"1537_CR50","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"Van Laar\u00a0JM, Farge\u00a0D, Sont\u00a0JK et\u00a0al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a\u00a0randomized clinical trial. JAMA 311:2490\u20132498. https:\/\/doi.org\/10.1001\/jama.2014.6368","journal-title":"JAMA"},{"key":"1537_CR51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/030097400750001897","volume":"29","author":"J Vencovsky","year":"2000","unstructured":"Vencovsky\u00a0J, Jarosova\u00a0K, Machacek\u00a0S et\u00a0al (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. ScandJRheumatol 29:95\u2013102","journal-title":"Scand.J.Rheumatol."},{"key":"1537_CR52","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh\u00a0M, Merkel\u00a0PA, Peh\u00a0CA et\u00a0al (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N\u00a0Engl J Med 382:622\u2013631. https:\/\/doi.org\/10.1056\/NEJMoa1803537","journal-title":"N Engl J Med"},{"key":"1537_CR53","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler\u00a0ME, Akuthota\u00a0P, Jayne\u00a0D et\u00a0al (2017) Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N\u00a0Engl J Med 376:1921\u20131932. 10.1056\/NEJMoa1702079","journal-title":"N Engl J Med"},{"key":"1537_CR54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311155","author":"ME Wechsler","year":"2024","unstructured":"Wechsler\u00a0ME, Nair\u00a0P, Terrier\u00a0B et\u00a0al (2024) Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2311155","journal-title":"N Engl J Med"},{"key":"1537_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/0961203313511555","volume":"23","author":"J Z\u00e1vada","year":"2014","unstructured":"Z\u00e1vada\u00a0J, Pesickov\u00e1\u00a0SS, Rysav\u00e1\u00a0R et\u00a0al (2014) Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A. Lupus 23:69\u201374. https:\/\/doi.org\/10.1177\/0961203313511555","journal-title":"Lupus"},{"key":"1537_CR56","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10067-018-4348-z","volume":"38","author":"M Zhang","year":"2019","unstructured":"Zhang\u00a0M, Qi\u00a0C, Zha\u00a0Y et\u00a0al (2019) Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a\u00a0randomized trial. Clin Rheumatol 38:859\u2013867. https:\/\/doi.org\/10.1007\/s10067-018-4348-z","journal-title":"Clin Rheumatol"},{"key":"1537_CR57","doi-asserted-by":"publisher","first-page":"e224492","DOI":"10.1001\/jamanetworkopen.2022.4492","volume":"5","author":"Z Zheng","year":"2022","unstructured":"Zheng\u00a0Z, Zhang\u00a0H, Peng\u00a0X et\u00a0al (2022) Effect of tacrolimus vs intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis: a\u00a0randomized clinical trial. JAMA Netw Open 5:e224492. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.4492","journal-title":"JAMA Netw Open"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01537-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01537-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01537-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T21:02:04Z","timestamp":1729112524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01537-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1537"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01537-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"5 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Hellmich: Beratung: AbbVie, AstraZeneca, Boehringer, GSK, Hansa, InflaRx, Novartis, Vifor; Referentent\u00e4tigkeit: AbbVie, Boehringer, BMS, GSK, MSD, Novartis, Pfizer, Vifor; Mitarbeit an Leitlinien (nicht verg\u00fctet): EULAR, DGRh. J.\u00a0Mucke: Beratung: AbbVie, AstraZeneca, BMS, GSK, Novartis, Otsuka; Referentent\u00e4tigkeit: AbbVie, AstraZeneca, BMS, GSK, Janssen, Lilly, Otsuka; Drittmittel: GSK, Sanofi; Mitarbeit an Leitlinien (nicht verg\u00fctet): EULAR, DGRh. M.\u00a0Aringer: Advisory Boards und\/oder Vortr\u00e4ge: AbbVie, AstraZeneca, BMS, GSK, Lilly, MSD, Mylan, Novartis, Pfizer, Roche; Mitarbeit an Leitlinien (nicht verg\u00fctet): EULAR, DGRh.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}